Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00606541 · ClinicalTrials.gov registry record · Early Phase 1
An Open Label, Double-blind Discontinuation Study of Quetiapine Extended Release(XR)
A Early Phase 1 study, sponsored by Duke University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 55
- Enrollment target
NCT00606541 is a Early Phase 1 study that was terminated before completion, run by Duke University. The registered enrollment target is 55 participants.
The verdict
NCT00606541, a Early Phase 1 study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
Purpose of Study: To examine 1) the short and long-term effectiveness and tolerability of quetiapine (extended release) XR for the treatment of social anxiety disorder (SAD); and 2) continuation effects of quetiapine XR in preventing SAD relapse.
Interventions
- DRUG Placebo
- DRUG Quetiapine XR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2008-01 |
| Est. Completion | 2012-11 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00606541
The ClinicalTrials.gov registry entry for NCT00606541 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00606541 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00606541 about?
NCT00606541 is a clinical study titled "An Open Label, Double-blind Discontinuation Study of Quetiapine Extended Release(XR)". Purpose of Study: To examine 1) the short and long-term effectiveness and tolerability of quetiapine (extended release) XR for the treatment of social anxiety disorder (SAD); and 2) continuation effects of quetiapine XR in preventing SAD relapse.
What is the current status of trial NCT00606541?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 55 participants. The study started on 2008-01. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00606541?
The interventions under investigation include: Placebo (DRUG), Quetiapine XR (DRUG).
Who is sponsoring clinical trial NCT00606541?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.